Results
From January 2021 to June 2022, a total of 29 patients (average age 66.0
± 8.6 years, 27.6% women) underwent IV sotalol load and 20 patients
(average age 60.4 ± 13.9 years, 65.0% women) underwent PO sotalol load.
The load was successfully completed in 22/29 (75.9%) patients receiving
IV sotalol and 20/20 (100%) of patients receiving oral sotalol,
although 7/20 of the oral sotalol patients (35.0%) required dose
reduction. Adverse events interrupting IV sotalol infusion included
bradycardia (7 patients, 24.1%) and QT prolongation (3 patients,
10.3%). No patients receiving IV or oral sotalol developed sustained
ventricular arrhythmias prior to discharge. LOS for patients completing
IV load was 2.6 days shorter (mean 1.0 vs 3.6, p < 0.001)
compared to LOS with oral load.